You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Harvard Business School
AstraZeneca
McKesson
Moodys
Express Scripts
Baxter

Last Updated: July 11, 2020

DrugPatentWatch Database Preview

Details for Patent: 9,364,656


Email this page to a colleague

» See Plans and Pricing

« Back to Dashboard

Which drugs does patent 9,364,656 protect, and when does it expire?

Patent 9,364,656 protects IONSYS and is included in one NDA.

This patent has eighty-eight patent family members in eighteen countries.

Summary for Patent: 9,364,656
Title:Method of storing an electrotransport drug delivery device
Abstract: A switch operated therapeutic agent delivery device is described. The device comprises two parts, which are assembled by a user prior to use. A first part contains a power supply and circuitry for the device; and a second part comprises electrodes and reservoirs containing the therapeutic agent to be delivered. The action of combining the two parts of the device causes the two parts to be irreversibly coupled together, completes an electrical connection between the two parts, and closes one or more switches, thereby connecting a power source, such as a battery, into the device's circuitry, thereby powering the device on so that it is ready for use. The device can then be attached to a patient, who can operate the device by pressing a button in a proper sequence.
Inventor(s): Netzel; Zita S. (Los Altos, CA), Lemke; John (Pleasanton, CA), Seward; David (Seattle, WA), Read; Brian W. (Brier, WA), White; Bradley E. (Lebanon, OH), Chen; Corinna X. (Oakland, CA), Hayter; Paul (Mountain View, CA)
Assignee: Incline Therapeutics, Inc. (Redwood City, CA) Alza Corporation (Vacaville, CA)
Application Number:14/002,909
Patent Claim Types:
see list of patent claims
Use; Delivery; Device;

Drugs Protected by US Patent 9,364,656

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
The Medicines Co IONSYS fentanyl hydrochloride SYSTEM;IONTOPHORESIS, TRANSDERMAL 021338-001 May 22, 2006 DISCN Yes No   Start Trial   Start Trial METHOD FOR IONTOPHORETIC TRANSDERMAL DELIVERY OF FENTANYL HYDROCHLORIDE   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 9,364,656

PCT Information
PCT FiledMarch 09, 2012PCT Application Number:PCT/US2012/028400
PCT Publication Date:October 04, 2012PCT Publication Number: WO2012/134767

International Family Members for US Patent 9,364,656

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia 2012238095   Start Trial
Australia 2012238096   Start Trial
Australia 2013266914   Start Trial
Australia 2013274873   Start Trial
Australia 2015271708   Start Trial
Brazil 112013024783   Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Medtronic
Harvard Business School
Merck
Dow
Johnson and Johnson
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.